Concomitant use of a PARP inhibitor with docetaxel significantly increased apoptosis in these cells, suggesting a role for PARP inhibition in sensitizing cancers with high CHFR activity to microtubule inhibitors (75). This evidence concerns the gene PARP1 and cancer.